Affinity Asset Advisors, LLC 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Affinity Asset Advisors, LLC disclosed 86 US equity positions worth $1.1bn in its Q3 2025 13F filing. The largest position was VRNA at 6.2% of the reported book, followed by INSM and SPY. Against the Q2 2025 filing, it opened 8 new positions, added to 24 and reduced 11 among the top 50 holdings.
What did Affinity Asset Advisors, LLC own in Q3 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | VRNA VERONA PHARMA PLC | 6.2% | $66.7m | 625,000 | 2% | added | |
| 2 | INSM INSMED INC | Healthcare | 6.0% | $64.8m | 450,000 | -5% | reduced |
| 3 | SPY SPDR S&P 500 ETF TR | 5.2% | $56.3m | 84,490 | – | new | |
| 4 | XENE XENON PHARMACEUTICALS INC | Healthcare | 5.2% | $56.2m | 1,400,000 | 27% | added |
| 5 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 4.9% | $52.7m | 115,000 | 44% | added |
| 6 | APGE APOGEE THERAPEUTICS INC | Healthcare | 4.3% | $46.6m | 1,173,426 | 70% | added |
| 7 | ACLXGBX ARCELLX INC | 3.8% | $41.0m | 500,000 | 1% | added | |
| 8 | ALKS ALKERMES PLC | Healthcare | 3.5% | $37.5m | 1,250,000 | 25% | added |
| 9 | NUVALENT INC | 3.1% | $33.2m | 384,417 | -7% | reduced | |
| 10 | ABVX ABIVAX SA | 2.8% | $30.6m | 360,000 | 260% | added | |
| 11 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 2.6% | $28.4m | 750,000 | -17% | reduced |
| 12 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 2.6% | $28.3m | 1,400,000 | 0% | held |
| 13 | MERUS N V | 2.5% | $26.9m | 285,769 | 308% | added | |
| 14 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.5% | $26.8m | 1,107,162 | 23% | added | |
| 15 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 2.4% | $25.7m | 3,870,527 | 8% | added |
| 16 | TRVI TREVI THERAPEUTICS INC | Healthcare | 2.4% | $25.6m | 2,800,000 | 10% | added |
| 17 | SYRE SPYRE THERAPEUTICS INC | 2.2% | $23.8m | 1,419,299 | 134% | added | |
| 18 | RZLT REZOLUTE INC | 1.8% | $19.7m | 2,100,000 | -5% | reduced | |
| 19 | CYTK CYTOKINETICS INC | Healthcare | 1.8% | $19.2m | 350,000 | – | new |
| 20 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.7% | $18.4m | 959,180 | 59% | added |
| 21 | QURE UNIQURE NV | 1.6% | $17.5m | 300,000 | 122% | added | |
| 22 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.4% | $15.4m | 2,100,000 | 5% | added |
| 23 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.4% | $14.7m | 220,600 | -50% | reduced |
| 24 | SLNOEUR SOLENO THERAPEUTICS INC | 1.3% | $13.5m | 200,000 | – | new | |
| 25 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.2% | $12.8m | 1,006,217 | 66% | added |
| 26 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 1.2% | $12.7m | 310,000 | -7% | reduced |
| 27 | KARYOPHARM THERAPEUTICS INC | 1.2% | $12.5m | 15,250,000 | 0% | held | |
| 28 | VTYXUSD VENTYX BIOSCIENCES INC | 1.1% | $12.2m | 3,924,415 | -13% | reduced | |
| 29 | ROIV ROIVANT SCIENCES LTD | Healthcare | 1.1% | $12.1m | 800,000 | 100% | added |
| 30 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.1% | $11.9m | 500,000 | -48% | reduced |
| 31 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 1.0% | $10.3m | 262,100 | – | new |
| 32 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.9% | $9.8m | 3,000,000 | 1400% | added |
| 33 | ERAS ERASCA INC | Healthcare | 0.9% | $9.3m | 4,285,787 | 5% | added |
| 34 | NRIX NURIX THERAPEUTICS INC | Healthcare | 0.8% | $8.9m | 967,620 | 0% | held |
| 35 | VERA VERA THERAPEUTICS INC | Healthcare | 0.8% | $8.8m | 303,330 | -44% | reduced |
| 36 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.8% | $8.2m | 400,000 | 0% | held |
| 37 | TVTX TRAVERE THERAPEUTICS INC | 0.7% | $7.9m | 7,000,000 | 0% | held | |
| 38 | NEWAMSTERDAM PHARMA COMPANY | 0.7% | $7.8m | 275,000 | 0% | held | |
| 39 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.7% | $7.8m | 300,000 | – | new |
| 40 | PROQR THRAPEUTICS N V | 0.7% | $7.7m | 3,600,000 | 3% | added | |
| 41 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 0.7% | $7.4m | 125,000 | – | new |
| 42 | AKBA AKEBIA THERAPEUTICS INC | Healthcare | 0.6% | $6.7m | 2,450,000 | 26% | added |
| 43 | MNPR MONOPAR THERAPEUTICS INC | 0.6% | $6.5m | 79,483 | 18% | added | |
| 44 | ZURA ZURA BIO LTD | Healthcare | 0.5% | $5.5m | 1,274,351 | 471% | added |
| 45 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.5% | $5.4m | 250,000 | -36% | reduced |
| 46 | SVRA SAVARA INC | Healthcare | 0.5% | $5.4m | 1,500,000 | 200% | added |
| 47 | IMVT IMMUNOVANT INC | Healthcare | 0.4% | $4.8m | 300,000 | – | new |
| 48 | OMEROS CORP | 0.4% | $4.7m | 5,525,000 | -39% | reduced | |
| 49 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.4% | $4.7m | 100,000 | – | new |
| 50 | PCVX VAXCYTE INC | Healthcare | 0.4% | $4.5m | 125,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.